📋 Regulatory Action / Label Change
The article reports FDA approval of asundexian (Sunharbo) 50 mg tablets, described as the first approved factor XIa inhibitor. Its indication covers combination treatment with antiplatelet therapy after recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. Approval was supported by OCEANIC-STROKE, which randomized 12,327 adults to once-daily asundexian or placebo alongside antiplatelet therapy. Treatment began within 72 hours of symptom onset; median treatment lasted 14.2 months.
Professional Impact
- Asundexian reduced ischemic stroke occurrence by 26% versus placebo, with both groups receiving antiplatelet therapy.
- Overall major bleeding rates were similar, but increased risk was reported in patients older than 75 and during the first 90 days.
- Gastrointestinal bleeding was more frequent with asundexian; diarrhea occurred in at least 3% of treated patients.
- Bayer reported consistent efficacy across key subgroups, including stroke subtype, severity, and planned antiplatelet regimen.
- Asundexian is not approved for stroke prevention in atrial fibrillation and is not recommended in moderate or severe hepatic impairment.
- Combined P-glycoprotein and strong CYP3A4 inducers, including carbamazepine, are not recommended because they may reduce efficacy.
Action Items
- Withhold treatment at least 24 hours before elective surgery or invasive procedures, according to the FDA advice cited.
- Withhold treatment for at least 24 hours after thrombolysis for acute ischemic stroke.
- Review the reported restrictions concerning interacting medications, hepatic impairment, and use outside the approved stroke-prevention population.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS